377 related articles for article (PubMed ID: 11567988)
21. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
22. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
[TBL] [Abstract][Full Text] [Related]
23. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.
van Rood JJ; Loberiza FR; Zhang MJ; Oudshoorn M; Claas F; Cairo MS; Champlin RE; Gale RP; Ringdén O; Hows JM; Horowitz MH
Blood; 2002 Mar; 99(5):1572-7. PubMed ID: 11861270
[TBL] [Abstract][Full Text] [Related]
24. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors.
Anasetti C; Hansen JA
Transfus Sci; 1994 Sep; 15(3):221-30. PubMed ID: 10155543
[TBL] [Abstract][Full Text] [Related]
25. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
[TBL] [Abstract][Full Text] [Related]
26. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.
Laughlin MJ; Eapen M; Rubinstein P; Wagner JE; Zhang MJ; Champlin RE; Stevens C; Barker JN; Gale RP; Lazarus HM; Marks DI; van Rood JJ; Scaradavou A; Horowitz MM
N Engl J Med; 2004 Nov; 351(22):2265-75. PubMed ID: 15564543
[TBL] [Abstract][Full Text] [Related]
27. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program.
McGlave P; Bartsch G; Anasetti C; Ash R; Beatty P; Gajewski J; Kernan NA
Blood; 1993 Jan; 81(2):543-50. PubMed ID: 8422471
[TBL] [Abstract][Full Text] [Related]
28. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years.
Marks DI; Cullis JO; Ward KN; Lacey S; Syzdlo R; Hughes TP; Schwarer AP; Lutz E; Barrett AJ; Hows JM; Batchelor JR; Goldman JM
Ann Intern Med; 1993 Aug; 119(3):207-14. PubMed ID: 8391772
[TBL] [Abstract][Full Text] [Related]
30. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy.
Deeg HJ; Seidel K; Casper J; Anasetti C; Davies S; Gajeweski JL; Territo M; Ramsay N; Harris RE; Catro-Malaspina H; Collins R; Champlin R; Schoch G; King R; Howe C
Biol Blood Marrow Transplant; 1999; 5(4):243-52. PubMed ID: 10465104
[TBL] [Abstract][Full Text] [Related]
31. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
Wagner JL; Seidel K; Boeckh M; Storb R
Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
[TBL] [Abstract][Full Text] [Related]
32. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
[TBL] [Abstract][Full Text] [Related]
33. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program.
Filipovich AH; Stone JV; Tomany SC; Ireland M; Kollman C; Pelz CJ; Casper JT; Cowan MJ; Edwards JR; Fasth A; Gale RP; Junker A; Kamani NR; Loechelt BJ; Pietryga DW; Ringdén O; Vowels M; Hegland J; Williams AV; Klein JP; Sobocinski KA; Rowlings PA; Horowitz MM
Blood; 2001 Mar; 97(6):1598-603. PubMed ID: 11238097
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience.
Vela-Ojeda J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; Rosas-Cabral A; Esparza MG; García-Chávez J; García-León LD; González-Llaven J
Arch Med Res; 2000; 31(2):206-9. PubMed ID: 10880729
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation.
Weisdorf D; Hakke R; Blazar B; Miller W; McGlave P; Ramsay N; Kersey J; Filipovich A
Transplantation; 1991 Jun; 51(6):1197-203. PubMed ID: 2048196
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group.
Phillips GL; Barnett MJ; Brain MC; Chan KW; Huebsch LB; Klingemann HG; Meharchand J; Reece DE; Rybka WB; Shepherd JD
Bone Marrow Transplant; 1991 Dec; 8(6):477-87. PubMed ID: 1790428
[TBL] [Abstract][Full Text] [Related]
37. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia.
Elmaagacli AH; Basoglu S; Peceny R; Trenschel R; Ottinger H; Lollert A; Runde V; Grosse-Wilde H; Beelen DW; Schaefer UW
Blood; 2002 Feb; 99(4):1130-5. PubMed ID: 11830457
[TBL] [Abstract][Full Text] [Related]
38. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.
Kernan NA; Bartsch G; Ash RC; Beatty PG; Champlin R; Filipovich A; Gajewski J; Hansen JA; Henslee-Downey J; McCullough J
N Engl J Med; 1993 Mar; 328(9):593-602. PubMed ID: 8429851
[TBL] [Abstract][Full Text] [Related]
39. Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Group (GITMO).
Dini G; Cancedda R; Locatelli F; Bosi A; Bandini G; Alessandrino EP; Porta F; Uderzo C; Messina C; Fagioli F; Arcese W; Marenco P; Fanin R; Falda M; Soligo D; La Nasa G; Giardini C; Pession A; Scimè R; Di Bartolomeo P; Bruno B; Garbarino L; Lamparelli T; Giorgiani G; Lanino E; Manzitti C; Bacigalupo A;
Haematologica; 2001 May; 86(5):451-6. PubMed ID: 11410406
[TBL] [Abstract][Full Text] [Related]
40. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
